NCT02051309View on ClinicalTrials.gov

Guanfacine Clinical Trial for Smoking Cessation

PHASE2CompletedINTERVENTIONAL
Enrollment

121

Participants

Timeline

Start Date

March 31, 2014

Primary Completion Date

November 30, 2020

Study Completion Date

November 30, 2020

Conditions
Smoking Cessation
Interventions
DRUG

Guanfacine

6mg/day ER with 3-week lead-in period. Maintained at steady state throughout 8 week treatment phase. After treatment phase, given taper supply of medication. Follow up at 1 month, 2 months and 6 months.

DRUG

Placebo

Trial Locations (1)

06519

Yale Center for Clinical Investigations, Yale University, New Haven

All Listed Sponsors
collaborator

National Institute on Drug Abuse (NIDA)

NIH

lead

Yale University

OTHER

NCT02051309 - Guanfacine Clinical Trial for Smoking Cessation | Biotech Hunter | Biotech Hunter